Literature DB >> 18931939

Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma.

Saminathan S Nathan1, Barry P Pereira, Ye-Fang Zhou, Anurag Gupta, Christian Dombrowski, Ritchie Soong, Robert W H Pho, Gary S Stein, Manuel Salto-Tellez, Simon M Cool, Andre J van Wijnen.   

Abstract

To understand the molecular etiology of osteosarcoma, we isolated and characterized a human osteosarcoma cell line (OS1). OS1 cells have high osteogenic potential in differentiation induction media. Molecular analysis reveals OS1 cells express the pocket protein pRB and the runt-related transcription factor Runx2. Strikingly, Runx2 is expressed at higher levels in OS1 cells than in human fetal osteoblasts. Both pRB and Runx2 have growth suppressive potential in osteoblasts and are key factors controlling competency for osteoblast differentiation. The high levels of Runx2 clearly suggest osteosarcomas may form from committed osteoblasts that have bypassed growth restrictions normally imposed by Runx2. Interestingly, OS1 cells do not exhibit p53 expression and thus lack a functional p53/p21 DNA damage response pathway as has been observed for other osteosarcoma cell types. Absence of this pathway predicts genomic instability and/or vulnerability to secondary mutations that may counteract the anti-proliferative activity of Runx2 that is normally observed in osteoblasts. We conclude OS1 cells provide a valuable cell culture model to examine molecular events that are responsible for the pathologic conversion of phenotypically normal osteoblast precursors into osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931939      PMCID: PMC2981062          DOI: 10.1007/s11033-008-9378-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  22 in total

1.  The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation.

Authors:  D M Thomas; S A Carty; D M Piscopo; J S Lee; W F Wang; W C Forrester; P W Hinds
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

Review 2.  The p53 tumor suppressor participates in multiple cell cycle checkpoints.

Authors:  Luciana E Giono; James J Manfredi
Journal:  J Cell Physiol       Date:  2006-10       Impact factor: 6.384

3.  The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts.

Authors:  Mario Galindo; Jitesh Pratap; Daniel W Young; Hayk Hovhannisyan; Hee-Jeong Im; Je-Yong Choi; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2005-03-21       Impact factor: 5.157

Review 4.  Etiology of osteosarcoma.

Authors:  Bruno Fuchs; Douglas J Pritchard
Journal:  Clin Orthop Relat Res       Date:  2002-04       Impact factor: 4.176

Review 5.  Molecular pathogenesis of osteosarcoma.

Authors:  Maya Kansara; David M Thomas
Journal:  DNA Cell Biol       Date:  2007-01       Impact factor: 3.311

6.  PolyA deletions in hereditary nonpolyposis colorectal cancer: mutations before a gatekeeper.

Authors:  Kyoung-Mee Kim; Reijo Salovaara; Jukka-Pekka Mecklin; Heikki J Järvinen; Lauri A Aaltonen; Darryl Shibata
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

7.  Cyclin D1-cdk4 induce runx2 ubiquitination and degradation.

Authors:  Run Shen; Xiumei Wang; Hicham Drissi; Fang Liu; Regis J O'Keefe; Di Chen
Journal:  J Biol Chem       Date:  2006-04-13       Impact factor: 5.157

8.  A new method for determining the status of p53 in tumor cell lines of different origin.

Authors:  Andrei L Gartel; Claudine Feliciano; Angela L Tyner
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

9.  Tumor suppressor pRB functions as a co-repressor of the CCAAT displacement protein (CDP/cut) to regulate cell cycle controlled histone H4 transcription.

Authors:  Sunita Gupta; Mai X Luong; Sylvia A Bleuming; Angela Miele; Michael Luong; Daniel Young; Erik S Knudsen; Andre J Van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2003-09       Impact factor: 6.384

10.  Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.

Authors:  Jennifer J Westendorf; S Kaleem Zaidi; Jonathan E Cascino; Rachel Kahler; André J van Wijnen; Jane B Lian; Minoru Yoshida; Gary S Stein; Xiaodong Li
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

View more
  33 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  CREB-binding protein silencing inhibits thrombin-induced endothelial progenitor cells angiogenesis.

Authors:  Hong Jiang; Si-si Chen; Jian Yang; Jing Chen; Bo He; Li-hua Zhu; Lang Wang
Journal:  Mol Biol Rep       Date:  2011-06-14       Impact factor: 2.316

3.  Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Authors:  Scott M Riester; Jorge Torres-Mora; Amel Dudakovic; Emily T Camilleri; Wei Wang; Fuhua Xu; Roman R Thaler; Jared M Evans; René Zwartbol; Inge H Briaire-de Bruijn; Avudaiappan Maran; Andrew L Folpe; Carrie Y Inwards; Peter S Rose; Thomas C Shives; Michael J Yaszemski; Franklin H Sim; David R Deyle; Annalise N Larson; Mario A Galindo; Arjen G H Cleven; Andre M Oliveira; Anne-Marie Cleton-Jansen; Judith V M G Bovée; Andre J van Wijnen
Journal:  J Orthop Res       Date:  2016-06-28       Impact factor: 3.494

Review 4.  Metastatic bone disease: role of transcription factors and future targets.

Authors:  Jitesh Pratap; Jane B Lian; Gary S Stein
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

5.  RUNX2 RNA interference inhibits the invasion of osteosarcoma.

Authors:  Heng Zeng; Xiaotao Xu
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

6.  Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma.

Authors:  Mingfu Yang; Yong Pan; Yue Zhou
Journal:  Tumour Biol       Date:  2015-03-04

7.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

8.  S100A16 inhibits osteogenesis but stimulates adipogenesis.

Authors:  Dong Li; Rihua Zhang; Weidong Zhu; Yi Xue; Yuanyuan Zhang; Qiong Huang; Menglan Liu; Yun Liu
Journal:  Mol Biol Rep       Date:  2013-03-25       Impact factor: 2.316

9.  Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression.

Authors:  Jitesh Pratap; Karen M Imbalzano; Jean M Underwood; Nathalie Cohet; Karthiga Gokul; Jacqueline Akech; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Jeffrey A Nickerson; Jane B Lian; Gary S Stein
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

10.  Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer.

Authors:  Kakoli Das; David Tai Leong; Anurag Gupta; Liang Shen; Thomas Putti; Gary S Stein; Andre J van Wijnen; Manuel Salto-Tellez
Journal:  Eur J Cancer       Date:  2009-07-24       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.